Indication
Recurrent Islet Cell Carcinoma
3 clinical trials
1 product
4 drugs
Clinical trial
A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsStatus: Completed, Estimated PCD: 2018-01-01
Drug
UTD1Product
TMZDrug
AtezolizumabClinical trial
A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the LiverStatus: Terminated, Estimated PCD: 2017-07-19
Drug
everolimusClinical trial
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine TumorsStatus: Active (not recruiting), Estimated PCD: 2021-05-26
Drug
letrozole